Education
About Us
Working with TipRanks
Follow Us
Opthea Limited (CKDXF)
OTHER OTC:CKDXF
CKDXF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.29 - $0.57
Previous CloseN/A
Volume9.90K
Average Volume (3M)0.00
Market Cap
$473.34M
Enterprise ValueN/A
Total Cash (Recent Filing)$172.47M
Total Debt (Recent Filing)$141.65M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Aug 28, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding1,231,287,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.34Price Target Upside-29.17% Downside
Rating ConsensusHold
Number of Analyst Covering3
---
Opthea News
PremiumCompany Announcements
JPMorgan Ceases Substantial Holding in Opthea
PremiumCompany Announcements
Opthea Halts Wet AMD Trials and Cuts Workforce Amid Financial Uncertainty
PremiumCompany Announcements
Opthea Announces Major Workforce Reduction Following Trial Setbacks
PremiumCompany Announcements
Opthea Limited’s Securities Suspended Due to Financial Concerns
PremiumCompany Announcements
Opthea Halts Wet AMD Trials Following Unsuccessful Phase 3 Results
PremiumCompany Announcements
JPMorgan Chase Acquires Substantial Stake in Opthea Limited
---
Options Prices
Currently, No data available
---
Ownership Overview
0.02%
Insiders
2.74% Mutual Funds
― Other Institutional Investors
95.72% Public Companies and
Individual Investors
CKDXF FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest stock price was $0.29 and its highest was $0.57 in the past 12 months.
What is Opthea Limited’s market cap?
Opthea Limited’s market cap is $473.34M.
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Aug 28, 2025 which is in 104 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Feb 27, 2025. The company reported -$0.108 earnings per share for the quarter, missing the consensus estimate of -$0.016 by -$0.092.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Overvalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate is -0.04.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,231,287,400 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of -$0.108 in its last earnings report, missing expectations of -$0.016. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in CKDXF
---
Opthea Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.34 (-29.17% Downside)
$0.34 (-29.17% Downside)
Blogger Sentiment
Bullish
CKDXF Sentiment 86%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
---
CKDXF Stock 12 Month Forecast
Average Price Target
$0.34
▼(-29.17% Downside)
Technical Analysis
Biotron
―
Imugene Limited
―
Paradigm Biopharmaceuticals Ltd.
―
PYC Therapeutics Limited
―
Race Oncology Ltd.
―
---